Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development

GlobeNewswire December 5, 2015

Achillion Reports Third Quarter And Nine Month 2015 Financial Results

GlobeNewswire November 5, 2015

Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology Detailing Novel Results With Factor D Inhibitors

GlobeNewswire November 5, 2015

Achillion to Present at the Credit Suisse 24th Annual Healthcare Conference

GlobeNewswire November 2, 2015

Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of AL-335, Odalasvir (ACH-3102), and Simeprevir for the Treatment of Genotype 1 Chronic HCV

GlobeNewswire October 16, 2015

Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

GlobeNewswire September 17, 2015

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire September 1, 2015

Achillion Reports Second Quarter and Six Month 2015 Financial Results

GlobeNewswire August 10, 2015

Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335 Pharmacokinetics

GlobeNewswire August 3, 2015

Achillion to Present at the JMP Securities Life Sciences Conference 2015

GlobeNewswire June 18, 2015

Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen

GlobeNewswire May 19, 2015

Achillion Reports First Quarter 2015 Financial Results

GlobeNewswire May 7, 2015

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire April 30, 2015

Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress

GlobeNewswire April 25, 2015

Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL)

GlobeNewswire April 8, 2015

Achillion Reports 2014 Fourth Quarter and Year-End Financial Results

GlobeNewswire March 5, 2015

Achillion Pharmaceuticals Announces Closing of Public Offering of Common Stock

GlobeNewswire February 18, 2015

Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 11, 2015

Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire February 10, 2015

Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

GlobeNewswire February 9, 2015